文献速递肾小球疾病慢性肾脏病

Sparsentan 3期 DUPLEX 研究:局灶节段性肾小球硬化患者基线特征

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
PubMed 文献 · Kidney Int Rep · 2024-01-28

DUPLEX 是评估 sparsentan 对比厄贝沙坦治疗 FSGS 的全球多中心随机双盲3期试验。本文描述371例随机患者的基线特征:中位年龄42岁,中位 UP/C 3.0 g/g,42.6% 达肾病范围蛋白尿,eGFR 均匀分布于 CKD 1-3b 期,9.4% 携带足细胞基因致病变异。

要点

  • 中位 UP/C 3.0 g/g,42.6% 达肾病范围蛋白尿。
  • eGFR 均匀分布于 CKD 1-3b 期,涵盖早期至中晚期。
  • 9.4% 可评估样本携带足细胞基因致病变异。

核心结论

  • DUPLEX 入组了迄今最大规模、地理分布广泛且临床多样的 FSGS 人群,有助于表征 sparsentan 的治疗效应。

研究设计与样本

  • DUPLEX(NCT03493685)为全球多中心、随机、双盲、平行组、活性对照3期研究,比较 sparsentan 800 mg 每日一次与厄贝沙坦 300 mg 每日一次。
  • 入组年龄8至75岁(美国/英国)或18至75岁(美国/英国以外),体重≥20 kg,经活检证实 FSGS 或记录有与 FSGS 相关的足细胞蛋白基因突变,且 UP/C≥1.5 g/g。
  • 基线特征按治疗分配盲态进行描述性报告,主要分析人群为371例随机并接受研究药物的患者(336例成人,35例儿童[<18岁])。

主要发现

  • 中位年龄42岁;种族分布为白人73.0%、亚裔13.2%、黑种人/非裔美国人6.7%、其他种族7.0%。
  • 地区分布为北美38.8%、欧洲36.1%、南美12.7%、亚太12.4%。
  • 基线中位 UP/C 为3.0 g/g;42.6% 达肾病范围蛋白尿(成人 UP/C>3.5 g/g,儿童>2.0 g/g)。
  • 患者均匀分布于对应 CKD 1至3b期的 eGFR 类别。
  • 352例可评估样本中,33例(9.4%)具有足细胞结构完整性和功能必需基因的致病或可能致病变异(P/LP),27例(7.7%)具有 P/LP 胶原基因(COL4A3/4/5)变异,14例(4.0%)具有高风险 APOL1 基因型。

临床怎么用

  • DUPLEX 基线特征提示 sparsentan 的疗效与安全性数据将覆盖从 CKD 1期至3b期、伴不同蛋白尿水平的广泛 FSGS 人群。

局限性

  • 本文仅报告盲态基线特征,未报告治疗结局或组间比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The phase 3 DUPLEX trial is evaluating sparsentan, a novel, nonimmunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS). METHODS: DUPLEX (NCT03493685) is a global, multicenter, randomized, double-blind, parallel-group, active-controlled study evaluating the efficacy and safety of sparsentan 800 mg once daily versus irbesartan 300 mg once daily in patients aged 8 to 75 years (USA/UK) and 18 to 75 years (ex-USA/UK) weighing ≥20 kg with biopsy-proven FSGS or documented genetic mutation in a podocyte protein associated with FSGS, and urine protein-to-creatinine ratio (UP/C) ≥1.5 g/g. Baseline characteristics blinded to treatment allocation are reported descriptively. RESULTS: The primary analysis population includes 371 patients (336 adult, 35 pediatric [<18 years]) who were randomized and received study drug (median age, 42 years). Patients were White (73.0%), Asian (13.2%), Black/African American (6.7%), or Other race (7.0%); and from North America (38.8%), Europe (36.1%), South America (12.7%), or Asia Pacific (12.4%). Baseline median UP/C was 3.0 g/g; 42.6% in nephrotic-range (UP/C >3.5 g/g [adults]; >2.0 g/g [pediatrics]). Patients were evenly distributed across estimated glomerular filtration rate (eGFR) categories corresponding to chronic kidney disease (CKD) stages 1 to 3b. Thirty-three patients (9.4% of 352 evaluable samples) had pathogenic or likely pathogenic (P/LP) variants of genes essential to podocyte structural integrity and function, 27 (7.7%) had P/LP collagen gene (COL4A3/4/5) variants, and 14 (4.0%) had high-risk APOL1 genotypes. CONCLUSIONS: Patient enrollment in DUPLEX, the largest interventional study in FSGS to date, will enable important characterization of the treatment effect of sparsentan in a geographically broad and clinically diverse FSGS population.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Trachtman H, Radhakrishnan J, Rheault MN, et al. Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney Int Rep. 2024. PMID: 38765567. doi:10.1016/j.ekir.2024.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。